ArticleCurrent drug targets2025
RMNet: An RNA m6A Cross-species Methylation Detection Method for Nanopore Sequencing.
Article in Current drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- AGCLD: an adaptive graph contrastive learning method with denoising for spatial domain identification.Briefings in bioinformatics · 2026Article
- The impact of m6A modified cargo conveyed by exosomes on the tumor microenvironment.Discover oncology · 2026Review
- MeDReaders 2.0: an updated database for modified DNA readers.BMC genomics · 2026Article
- Tumor ecosystem subtyping of breast cancer based on somatic mutations and network propagation reveals distinct prognostic and genomic landscapes.Frontiers in genetics · 2026Article
- Machine Learning-Based Integration of Single-Cell and Bulk Transcriptome Reveals Coagulation Signature and Phenotypic Heterogeneity in Hepatocellular Carcinoma.IET systems biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionN6-methyladenosine (m6A) is the most prevalent RNA modification in eukaryotic cells, influencing RNA lifecycle processes. Existing m6A detection methods, such as wet-lab techniques and statistical approaches, are time-consuming, labor-intensive, or require control samples, while machine learning models often lack cross-species applicability. This study aims to develop RMNet, a robust cross-species m6A detection method using nanopore sequencing.
methodsRMNet employs Conformer and RNN architectures, integrating signal and alignment features from nanopore sequencing data. Contrastive learning enhances differentiation between m6A and non-m6A sites. The model was trained and tested on datasets from synthesized RNA, Arabidopsis, and human samples, using a single set of model weights.
resultsRMNet achieved state-of-the-art performance with accuracies of 99.7% for synthesized RNA, 78.8% for Arabidopsis, and 88.9% for human datasets. It outperformed existing methods (m6Anet, DENA, and RedNano) across six metrics, including AUC and AUPR, demonstrating robust cross-species generalization. DISCUSSION: RMNet's ability to detect m6A sites across diverse species with a single model addresses limitations of species-specific models. Its high sensitivity and feature representation enable applications in cancer research, neurodevelopmental studies, and plant biology. Limitations include higher error rates in human datasets for thymine-rich k-mers, likely due to complex secondary structures.
conclusionRMNet provides an efficient, powerful tool for cross-species m6A detection, advancing epitranscriptomics research with potential applications in precision medicine and agricultural science.
Indexed as
Identifiers
40621754What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.